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The Peanut Allergic Patient: Diagnosis,
Treatment, and Prevention
Daniel W. Hill, MSN, FNP, Jane H. Lassetter, PhD, RN, and
Craig Nuttall, DNP, FNP-C
ABSTRACT

The prevalence of peanut allergies (PAs) continues to rise through recent decades,
despite the best attempts to reverse that trend. PAs are unpredictable and can be lifethreatening. Therefore, it is imperative that nurse practitioners (NPs) are fully aware of
the most recent guidelines and evidence regarding diagnosis, treatment, and
prevention of PAs. This article presents information on the current research in the
diagnosis and treatment of PAs as well as the latest guidelines established to prevent PA
development. NPs should understand this information, allowing them to provide the
best care possible for their patients.
Keywords: diagnosis, immunotherapy, peanut allergy, prevention guidelines,
treatment
Ó 2017 Elsevier Inc. All rights reserved.

W

hile playing at a friend’s house, an 11year-old boy was offered a snack, a
pretzel ﬁlled with peanut butter. After
realizing what he had bitten into, he immediately spat
it out, knowing he was severely allergic to peanuts.
His mother was notiﬁed and rushed over with an
epinephrine injection. Unfortunately, her response
was too late. This boy passed away from an
anaphylactic reaction to peanuts resulting in cardiac
arrest.1
Sadly, lethal situations like this one occur periodically as peanut allergies (PAs) become more
prevalent. The most recent United States estimate of
PA prevalence is 2% according to a parent-reported
survey.2 However, a 2014 study in Massachusetts
found 4.9% of their sample tested positive for PAs.3
PAs typically develop in the ﬁrst years of life, and
remission is unlikely; only 20% will outgrow their
allergy by the time they start school.2,4 Additionally,
the likelihood of the resolution of PAs is much lower
than the resolution rate of other allergenic foods.2

American Association of Nurse Practitioners (AANP) members may
receive 1.0 continuing education contact hours, including 0.25 pharmacology credit, approved by AANP, by reading this article and
completing the online posttest and evaluation at aanp.inreachce.com.
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A PA diagnosis can be frightening and lifethreatening. Consequently, a PA alters what one eats
and creates anxiety for people with PAs, their families,
and friends.5 Some countries require precautionary
advisory labels to indicate any possibility of the
product containing peanuts, yet these labels may be
inconsistent and inadequately represent the possibility
of peanut contamination.6 Other methods to promote
public safety include increasing the awareness of PAs
and implementing policies and practices that improve
safety at schools and early care/education programs.7
Despite strategies to cope with PAs and minimize
exposure, a risk of accidental exposure remains.
Avoidance has been the only recommendation
over the past several decades.8 However, recent studies
show promise in the effectiveness and safety of oral
immunotherapy (OIT),9 sublingual immunotherapy
(SLIT),10 and epicutaneous immunotherapy (EPIT).11
Additionally, improved diagnostic testing provides
more accurate results while minimizing risk.12
Because of the increasing PA prevalence,3 nurse
practitioners (NPs) should understand PA development, the available tests and treatments, and the
associated risks. With this knowledge, NPs can
educate patients about appropriate management
and help them cope with their allergy.
Volume 13, Issue 8, September 2017

The purpose of this clinical feature is to present what
NPs need to know about their role in the care of PA
patients. Speciﬁcally, it includes an overview of PA
development, typical history and physical examination
(PE) ﬁndings, the latest research on effective diagnostic
and treatment techniques, the latest guidelines on preventing PAs, and tips for teaching patients and families.
DEVELOPMENT OF PA

Understanding allergy development may reveal a
pathway to prevention. Several theories attempt to
explain PA development, yet the exact cause remains
unknown. Theories include the hygiene hypothesis,13 maternal-fetal pathway,14 external exposure,15
and the dietary hypothesis.13
According to the hygiene hypothesis, improved
sanitation minimizes exposure to bacteria and viruses,
which previously strengthened immune systems.
Without these exposures, some people react against
nonharmful agents13 like peanuts.
The maternal-fetal pathway hypothesizes initial
exposure to peanuts occurs in utero and/or through
breastfeeding, causing infants as young as 4 months
old to test positive to peanuts.14 In contrast, maternal
ingestion of allergenic foods during pregnancy
provides protection against midchildhood allergies.3
According to the external exposure theory,
exposure occurs through inhalation or compromised
skin.15 If peanut exposure occurs at the compromised
site, the immune system might recognize peanuts as
an offending agent and react in subsequent exposures.
The dietary hypothesis is based on differences
between Western and Mediterranean diets. The
Mediterranean diet provides exposure to various
foods, including peanuts, which theoretically helps
the immune system recognize harmful agents.13 For
example, children in the United Kingdom have a PA
rate 10 times higher than their Israeli counterparts,
who began consuming peanuts earlier in life.16
CLINICAL PRESENTATION
History of Present Illness

The integumentary, cardiopulmonary, and gastrointestinal systems are most commonly affected with
food allergies.8 Therefore, patients with a PA
typically present with a history consistent with
allergic reactions including complaints of itching;
www.npjournal.org

rashes; hives; swelling; wheezing; coughing; voice
changes; or gastrointestinal issues including nausea,
vomiting, and diarrhea. The timing of symptoms
after ingestion is also important. A PA is a type 1
immunoglobulin E (IgE)-mediated response, and
symptoms occur rapidly after exposure, usually only
minutes later.14,15 The amount of peanuts consumed
contributes to the severity of the reaction.15 Other
cofactors that can inﬂuence the reaction threshold
and severity include recent exercise, current
medications, and comorbid conditions.8,12
Past Medical and Family History

Patients with a family history of PAs and/or concurrent diagnosis of eczema or asthma are at increased
risk for developing a PA. Eczema, asthma, and food
allergies are often concurrently diagnosed because of
an atopic gene.8 PAs develop in 25% to 30% of
patients with a strong atopic history.12 Similarly, 90%
of people with PAs have a history of eczema, asthma,
rhinitis, or other food allergies.15 Thus, NPs should
ask about these conditions or symptoms in patients
and family members. A concurrent diagnosis of a PA
and asthma, particularly if undertreated, increases the
risk of an anaphylactic reaction.15 Additionally,
patients with asthma have an increased likelihood of a
severe reaction during oral peanut challenges.17
Physical Examination

Patient history should be the primary cause to suspect
a PA because PE ﬁndings may be unremarkable at the
time of evaluation. NPs should evaluate all systems
affected by an allergic reaction, including integumentary, cardiopulmonary, and gastrointestinal,
because some symptoms may be overlooked by the
patient/family. Information gathered from the history
of present illness, past medical and family history, PE,
and timing of reaction help an NP decide whether to
order diagnostic testing or refer to a specialist who is a
provider trained and experienced in diagnostic testing,
the associated risks, and how to manage them.18
DIAGNOSIS

Early, accurate diagnosis is imperative because
anaphylaxis is more common in PAs than other
foodborne allergies.6 Diagnostic tools include oral
food challenges (OFCs), skin prick testing (SPT),
The Journal for Nurse Practitioners - JNP
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peanut-speciﬁc serum (sIgE), and component IgE
testing (cIgE). No one diagnostic test is perfect.19 Using
them in combination will provide more accurate
information than any one test alone. Additionally,
PA testing should be limited to patients with a history of
symptoms because positive results can occur in both SPT
and sIgE in people without a history of symptoms.12
Positive SPT and/or sIgE results without a history of
symptoms or peanut sensitization do not always indicate
a PA. In fact, the majority of the population who are
peanut sensitized are not allergic.12
OFCs

An OFC is typically supervised by a specialist and is
the “gold standard” for PA testing because it is the
most deﬁnitive test available,12 but it has ﬂaws. An
OFC is simple but can be time-consuming and
potentially dangerous. An allergic reaction of unpredictable severity may develop, with anaphylaxis
being the greatest risk.17 Any patient with a recent
history of anaphylaxis should not be tested using an
OFC.8 In an OFC, patients eat a peanut product and
are monitored for signs of an allergic reaction.
Emergency supplies and medications are available in
case a severe reaction develops. NPs should be
familiar with OFCs and the risks involved and
educate their patients accordingly.12
SPT

SPT is less risky but not as accurate as an OFC and is
typically performed by specialists.20 A skin prick
introduces a small amount of antigen into the tissue.
After 15 minutes, the allergen prick site is compared
with a control prick site and assessed for the
development of hives, indicating a reaction.
Typically, a wheal  3 mm indicates a PA but only if
paired with a positive history suggesting a PA.15
However, some studies used wheals of > 4 mm21 and
 8 mm20 to diagnose a PA, even without a positive
history. Limitations of SPT for PAs include low
speciﬁcity (30%), variability in concentration of test
reagents, pressure applied when pricking the skin,
location placed, and timing of reading results.12
sIgE Testing

sIgE testing measures the amount of peanut-speciﬁc
IgE in the patient’s serum. Elevated levels correlate
520
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with an increased likelihood of allergy. Sicherer and
Wood12 found sIgE concentrations above 15 kUA/L
had more than a 95% chance of clinical reactivity.
However, Dang et al20 found sIgE had a high
speciﬁcity (98%) but low sensitivity (26%) when
using the cutoff of 15 kUA/L to diagnose PAs with a
positive predictive value of 95%. Sensitivity refers to
the likelihood of a positive result if actually positive,
and speciﬁcity refers to the likelihood of a negative
result if negative. Therefore, a low speciﬁcity means
there is an increased risk of false-negative results. sIgE
testing can be completed in a primary care clinic but
requires access to a laboratory capable of running this
test. Correct test ordering and interpretation can be
complex. NPs unfamiliar with these tests should refer
patients to a specialist.15
cIgE Testing

cIgE is another blood test that can be completed in a
primary care clinic.20 This test measures IgE levels for
each of the identiﬁed peanut protein components,
which are Ara h1-h17.22 Each component has
properties that may correlate to an allergic response.12
Ara h1, 2, and 3 were more often positive in subjects
who failed OFC, and Ara h8 was more frequently
positive in people who passed OFC.19 Ara h2 was
more sensitive and speciﬁc for PAs than Ara h1, 3, 8, or
sIgE testing.19 Despite these results, increased Ara h2
has not been directly correlated to severe reactions.12
Nevertheless, Dang et al20 found cIgE more accurate
than either SPTs or sIgE in determining PAs. Their
participants ﬁrst underwent SPTs and OFCs to
determine allergy status and then completed sIgE and
cIgE for Ara h2. Results were then compared with
OFCs to determine testing accuracy. cIgE accurately
diagnosed more patients than either SPT or sIgE.
Using cIgE as a follow-up test to sIgE could minimize
the need for OFCs by as much as two thirds.20
Additional study is needed to further evaluate peanut
components among various populations.12
Each testing modality has beneﬁts and limitations.
OFCs remain the “gold standard” but have risks of
anaphylaxis.12,20 SPTs deliver quick results when
history suggests a PA.20 OFCs and SPTs are typically
performed by specialists.20 Conversely, Ara h2 and
sIgE testing can be performed in primary care clinics.
Current recommendations suggest that if patient
Volume 13, Issue 8, September 2017

history is positive for allergic reaction, then SPT or
sIgE may be sufﬁcient. If these test results are not
deﬁnitive, then an OFC is recommended.20 Patients
without a history of an allergic reaction should not be
tested because it is costly and can cause undue burden
on patients.12
TREATMENT

In addition to knowing about available tests, NPs
should be aware of current treatment options to
better educate patients. The initial treatment
recommendation should be avoidance,8 which can be
very difﬁcult.23 Beyond that, any patient diagnosed
with a PA should be prescribed EpiPens (Mylan,
Canonsburg, PA), or a similar product, because of the
risk of anaphylaxis.8,17 Antihistamines are beneﬁcial
for the treatment of acute mild reactions.24 Recent
advancements can help patients develop tolerance to
varying amounts of peanuts. This progress in
treatment will, hopefully, lead to complete
desensitization, allowing worry-free
peanut ingestion.
Investigational Treatment Modalities

Subcutaneous immunotherapy for PAs was associated
with a high rate of systematic adverse events (AEs),
some of which were severe, which necessitated
research on other modalities.25 Two investigational
treatment options are SLIT and OIT. SLIT is
administered by placing drops of peanut extract
under the tongue, and OIT is administered through
ingesting the allergen, typically peanut powder. Both
methods are relatively safe and effective in creating a
level of tolerance to peanuts.9,10
The administration of SLIT and OIT follows a
similar protocol, beginning with an escalation phase
followed by a maintenance phase. Therapy begins at
low doses, and the dose is increased every 1 to 2
weeks under clinic supervision. Patients take the
safely consumed dose at home until the next increase.
If an allergic reaction occurs, families treat as
instructed and notify the clinic, dosing adjustments
are made, and patients are again advanced as tolerated. Once the maintenance dose is reached, patients
continue on that same dose. The time frame for each
phase varies from several weeks or months (escalation) to years (maintenance).10,25
www.npjournal.org

SLIT doses are much lower than OIT doses because
sublingual administration is systemically absorbed faster
than oral administration. SLIT’s lower doses result in
fewer adverse events (AEs) than OIT. In a pilot study,
AEs occurred in 9% of SLIT doses and 43% of OIT
doses (P < .001).9 Reactions in both groups were
typically mild; however, moderate reactions and
reactions requiring antihistamines, beta2-agonists, and
epinephrine were more common in the OIT group.
Additionally, more participants withdrew because of
intolerable symptoms in the OIT group than the SLIT
group.9 Although this evidence suggests using SLIT,
effectiveness should be considered. In both groups,
participants experienced at least partial desensitization,
but differences between the groups were signiﬁcant.
The OIT group developed better desensitization,
tolerating an average of 24 peanuts compared with an
average of 1 or 2 peanuts in the SLIT group.9 Similarly,
Fleischer et al10 found that desensitization from SLIT
was not clinically signiﬁcant.
Unlike SLIT and OIT, EPIT is administered
through a patch placed on the skin. A recent study
compared 2 different strengths, 100 and 250 mg,
against placebo.11 Participants (N ¼ 74) went
through an escalation phase, which focused on
tolerance to the patch for longer time periods each
day, thereby increasing the amount absorbed.
Although the ongoing study is designed for 130
weeks, evaluation based on OFC results after 52
weeks indicated EPIT created greater tolerance to
peanuts with both the 100 and 250 mg doses than
placebo (P ¼ .005 and P ¼ .003, respectively).11 The
difference between the treatment groups was
insigniﬁcant (P ¼ .48). Children younger than 11
years responded best to treatment. Although there
were no severe reactions, mild AEs, usually limited to
the patch site, occurred in 79.8% of doses.11
SLIT, OIT, and EPIT show promise in treating
PAs, but studies are limited by small sample
sizes,9,10,23 high dropout rates,9,10 and exclusion of
subjects with history of anaphylaxis or other severe
reactions.9-11 Further study is needed.
MANAGEMENT
Prevention

The devastating nature of PAs has encouraged
research on PA prevention. Du Toit et al’s study,21
The Journal for Nurse Practitioners - JNP
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Learning Early about Peanut Allergy (LEAP), found
introducing peanut into the diet of high-risk infants
in their ﬁrst 11 months can reduce the risk of
developing PAs.21 Infants (4-11 months old) who
had severe eczema, egg allergy, or both were
classiﬁed as high risk. Children were excluded if they
were low risk (no history of egg allergy or severe
eczema) or they had an SPT result for peanuts larger
than 4 mm because this increased their likelihood of
being allergic.21 Participants were randomly assigned
into either the peanut consumption or peanut
avoidance group. Among participants with a negative
SPT (0 mm) at baseline, regular peanut consumption
resulted in an 86.1% relative reduction in PAs at 60
months of age with a PA prevalence of 13.7% in the
avoidance group and 1.9% in the consumption group
(95% conﬁdence interval, 3.4-20.3; P < 0.001).21
Among participants with a positive SPT (< 4 mm) at
baseline, regular peanut consumption resulted in a
70% relative reduction in PAs at 60 months of age
with a PA prevalence of 35.3% in the avoidance
group and 10.6% in the consumption group (95%
conﬁdence interval, 4.9-43.3; P ¼ 0.004).21
LEAP-ON, the follow-up study, involved the
same participants and researched whether early peanut consumption provided long-lasting tolerance.
After the LEAP study, the consumption group was
asked to abstain from peanuts for 12 months, and the
avoidance group continued avoiding peanuts.26 After
this 12-month period, the early peanut consumption
group had a signiﬁcantly lower PA prevalence (4.8%)
than the early peanut avoidance group (18.6%)
(P < .001). Although 3 children in the consumption
group became peanut allergic over the 12-month
period, the prevalence difference at 60 months versus
72 months was not statistically signiﬁcant (P ¼ .25).
Thus, LEAP-ON found a sustained beneﬁt from the
early introduction of peanuts.26
Perkin et al27 evaluated which age is best for
introducing allergenic foods into infants’ diets.
Inclusion criteria were being 3 months old and
being strictly breastfed. Participants were
randomized into 2 groups: standard (6 months) and
early (3 months) introduction. Introduced foods
included peanuts, cooked egg, cow’s milk, sesame,
whiteﬁsh, and wheat. The standard group began
introduction of these foods at 6 months of age at
522
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the parents’ discretion. The early group had
baseline SPTs completed, and, if positive, then
OFCs were completed. Those with a negative SPT
or OFC were instructed to continue with this
introduction protocol (ie, ﬁrst cow’s milk; then
peanut, cooked egg, whiteﬁsh, and sesame, in any
order; and, ﬁnally, wheat).27 If an SPT and OFC
were positive for any of these foods, participants
avoided those particular foods and continued per
protocol with the others. For peanuts, the early
introduction group had a lower prevalence (0/310)
of PAs compared with the standard introduction
group (13/525) (P ¼ .003) in the per-protocol
analysis.27 However, in the intention-to-treat
analysis, there was no statistical beneﬁt (P ¼ .11) in
the early introduction of peanuts at 3 months
compared with 6 months.27
Research has impacted practice guidelines. For
example, the LEAP study inﬂuenced the National
Institute of Allergy and Infectious Diseases to develop
the 2017 addendum to the 2010 Guidelines for the
Diagnosis and Management of Food Allergy in the
United States.18 The addendum recommends, when
appropriate, the early introduction of peanuts to prevent
PAs.18 Furthermore, it speciﬁes that products containing
peanuts should be introduced between 4 and 11 months
of age for most infants. The timing of introduction
coincides well with the introduction of solids into
infants’ diets. The guideline recommendations are for
speciﬁc groups of varying risk levels for developing PAs
(Table 1).18 The early introduction of peanuts to an
infant’s diet minimizes the risk of developing a PA but
does not eliminate the risk completely.21 Current
guidelines are essential for primary care providers to
understand and implement to help reverse the trend of
increasing PAs.
Role of the NP

NPs have important roles in PA prevention, diagnosis, and proper education in developing an allergy
plan. Additionally, NPs should help patients understand what to expect from the specialist and current
treatment options.
At a minimum, an allergy plan (Table 2) should
include the following: remaining safe with PAs and
avoiding exposure, identifying allergic reactions and/
or anaphylaxis, treating reactions, and referring to a
Volume 13, Issue 8, September 2017

Table 1. National Institute of Allergy and Infectious Diseases’ Addendum Guidelines for Early Peanut Introduction18
Risk level

Recommendations

Low (no eczema and no food allergies)

 Introduce peanuts freely into diet according to age-appropriate guidelines, family preferences, and cultural practices
 Introduce peanuts at home18

Moderate (mild to moderate eczema)

 Introduce peanuts around 6 months of age according to age-appropriate
guidelines, family preferences, and cultural practices
 Introduce other solids before peanuts to ensure developmental capability
 Introduce peanut at home or in ofﬁce18

High (severe eczema, egg allergy, or both)

 Introduce age-appropriate peanut-containing foods at 4-6 months of age
 Introduce other solids before peanuts to ensure developmental capability
 Evaluate peanut sIgE, SPT, or both before introducing peanut into diet and
follow recommendations based on results
 sIgE done in PCP ofﬁce, SPT with specialist
 sIgE < 0.35 kUA/L, introduce peanut into diet
 sIgE  0.35 kUA/L, refer to specialist
 SPT  2 mm, introduce peanut into diet
 SPT 3-7 mm, refer to specialist for OFC
 SPT  8 mm, avoid peanuts and refer to specialist18

Children with identiﬁed peanut allergy

 Strict avoidance
 In families with known peanut allergies, discuss risks and beneﬁts of
adding peanuts to an infant’s diet18

OFC ¼ oral food challenge; PCP ¼ primary care physician; sIgE ¼ peanut-speciﬁc immunoglobulin E; SPT ¼ skin prick test.

specialist.15 As mentioned previously, patients with a
suspected PA should be prescribed EpiPens.13 NPs
should emphasize the possibility of a biphasic
reaction, a secondary anaphylactic reaction that can
occur up to 72 hours after resolution of the initial
reaction.13 EpiPens come in pairs for this reason13 as
well as the need for backup in case an EpiPen is

faulty. Whenever an EpiPen is used, the patient
should be transported to the nearest hospital for
monitoring and further treatment.
CONCLUSION

PA prevalence has increased over recent decades,
which increases the likelihood that NPs will be

Table 2. Peanut Allergy Plan15
Safety






Identify reactions/anaphylaxis

 Watch for itching, rashes, hives, or swelling after peanut exposure8,15
 Anaphylaxis can include coughing, wheezing, fatigue, drop in BP, closing
of airway, and loss of consciousness15

Treatment

 For mild reactions treat with antihistamine24
 For severe reactions, use EpiPen as directed and go to the local emergency
department13
 Can use short-acting beta-agonist to help with symptoms after EpiPen
administration if asthmatic24

Refer to specialist

 If unable to manage symptoms or family would like further consultation
 See SPT/sIgE results in Table 118

Avoid peanuts, including restaurants with environmental exposure28
Read/trust nutrition fact labels28
Notify school/friends/family15,24
Keep EpiPen available

BP ¼ blood pressure; sIgE ¼ peanut-speciﬁc immunoglobulin E; SPT ¼ skin prick test.

www.npjournal.org
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involved in assessing and managing patients with PAs.
This article addressed the recent advancements in
diagnosis, treatment, and prevention that are important for NPs to understand. Developing desensitization through new immunotherapy options can
greatly improve the quality of life for patients
with PAs. Following the National Institute of Allergy
and Infectious Diseases guidelines for the management of food allergies can minimize PA development, and the implementation of an allergy plan
will improve safety in day-to-day living. NPs ﬁll
an important role in helping patients manage this
life-altering condition.
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